Artelo Biosciences(ARTL)
搜索文档
Artelo Biosciences(ARTL) - 2021 Q3 - Earnings Call Transcript
2021-08-19 03:29
Artelo Biosciences, Inc. (NASDAQ:ARTL) Q3 2021 Earnings Conference Call August 18, 2021 11:45 AM ET Company Participants Andy Yates - Chief Scientific Officer Conference Call Participants Unidentified Company Representative Thank you so much for everyone who’s joined this morning. During the presentations, if you have any questions, feel free to use the Q&A feature down below. For this presentation, we have Andy Yates from Artelo. If you want, take it away. Andy Yates Thank you very much, and good morning a ...
Artelo Biosciences, Inc. (ARTL) CEO Gregory Gorgas Presents at Q1 Virtual Investor Summit Conference (Transcript)
2021-03-24 03:20
Artelo Biosciences, Inc. (NASDAQ:ARTL) Q1 Virtual Investor Summit Conference March 23, 2021 1:00 PM ET Company Participants Gregory Gorgas - President & Chief Executive Officer Conference Call Participants Operator You have joined the meeting as an attendee, and will be muted throughout the meeting. Unidentified Company Representative Greg, please share your screen from your slide deck and take it away. Gregory Gorgas All right, thank you very much. And I just want to confirm, you can see my screen. Unident ...
Artelo Biosciences(ARTL) - 2020 Q4 - Annual Report
2020-11-04 21:08
10-K 1 artl_10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 333-249083 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Nevada (S ...
Artelo Biosciences(ARTL) - 2019 Q4 - Annual Report
2019-11-25 20:56
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2019 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 333-234372 Artelo Biosciences, Inc. (Exact name of registrant as specified in its charter) Nevada 33-1220924 (State or other juris ...